

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

SUPPLEMENTAL CONCERT PARTY AGREEMENT

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**” or “**we**”) on a voluntary basis.

BACKGROUND

On January 21, 2021, Dr. Jonathon Zhong Zhao (“**Dr. Zhao**”), Dr. Shengping Sam Zhong (“**Dr. Zhong**”), Dr. Zheng Li (“**Dr. Li**”), Ms. Na Wei (“**Ms. Wei**”), Zhuhai Tongqiao Investment Center (Limited Partnership) (“**Zhuhai Tongqiao**”), Hangzhou Fujiang Investment Partnership (Limited Partnership) (“**Hangzhou Fujiang**”), Zhuhai Guichuang Equity Investment Center (Limited Partnership) (currently known as Zhuhai Guichuang Investment Center (Limited Partnership), “**Zhuhai Guichuang**”), Huzhou Guiqiao Enterprise Management Partnership (Limited Partnership) (currently known as Hangzhou Guiqiao Enterprise Management Partnership (Limited Partnership), “**Hangzhou Guiqiao**”), WEA Enterprises, LLC (“**WEA**”) and Nanjing Yuyihui Investment Partnership (Limited Partnership) (currently known as Hangzhou Yuyihui Enterprise Management Partnership (Limited Partnership), “**Hangzhou Yuyihui**”) (each a “**Concert Party**” and collectively, the “**Concert Parties**”) entered into the concert party agreement (the “**Concert Party Agreement**”), pursuant to which the Concert Parties acknowledged that they have been acting in concert in respect of the decision-making at the Board and Shareholders’ level relating to the business operation, corporate governance and major issues of the Company and they agreed to continue to act in concert to control the decision-making and operation management of the Company at Board meetings and Shareholders’ meetings.

ENTERING INTO THE SUPPLEMENTAL CONCERT PARTY AGREEMENT

On April 2, 2026, the Company was informed by the Concert Parties that they have entered into a supplemental concert party agreement (the “**Supplemental Concert Party Agreement**”), pursuant to which WEA and Dr. Zhong are no longer members of the

Concert Parties and while all other remaining concert parties, including Dr. Zhao, Dr. Li, Ms. Wei, Zhuhai Tongqiao, Hangzhou Fujiang, Zhuhai Guichuang, Hangzhou Guiqiao and Hangzhou Yuyihui (each a “**New Concert Party**” and collectively, the “**New Concert Parties**”), will act in concert in relation to the exercise of voting rights attached to the issued shares of the Company (the “**Shares**”) held by each of them. Dr. Zhong holds 100% of the equity interest in WEA and is one of the early investors of the Company. Upon execution of the Supplemental Concert Party Agreement, each of WEA and Dr. Zhong shall cease to act in concert with the New Concert Parties and shall no longer be deemed to be interested in any Shares held by the New Concert Parties.

By virtue of the Supplemental Concert Party Agreement, the New Concert Parties are considered as a group of Shareholders acting in concert and they are deemed to be interested in each other’s interest in the Shares by virtue of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Immediately after the execution of the Supplemental Concert Party Agreement, the New Concert Parties are interested in a total of 84,697,302 Shares under Part XV of the SFO, representing approximately 24.61% of the entire issued share capital of the Company, and their respective shareholding percentages in the Company are as follows:

| Shareholders | Type of Shares | Number of Shares | Percentage of total issued share capital (approximately) |
|---------------------|-----------------------|-----------------------------|---|
| Dr. Zhao | H Shares | 42,719,796 ⁽¹⁾ | 12.41% |
| | Domestic Shares | 4,144,199 | 1.20% |
| Dr. Li | H Shares | 2,479,427 ⁽²⁾ | 0.72% |
| | Domestic Shares | — | — |
| Ms. Wei | H Shares | — | — |
| | Domestic Shares | — | — |
| Zhuhai Tongqiao | H Shares | 8,141,222 | 2.37% |
| | Domestic Shares | 1,015,198 | 0.30% |
| Hangzhou Fujiang | H Shares | 3,750,196 | 1.09% |
| | Domestic Shares | 568,294 | 0.17% |
| Zhuhai Guichuang | H Shares | 7,353,613 | 2.14% |
| | Domestic Shares | 1,095,857 | 0.32% |
| Hangzhou Guiqiao | H Shares | 7,488,498 | 2.18% |
| | Domestic Shares | 957,709 | 0.28% |
| Hangzhou Yuyihui | H Shares | 4,983,293 | 1.45% |
| | Domestic Shares | — | — |
| Total | | 84,697,302 | 24.61% |

Notes:

- (1) This includes (i) 38,719,796 H Shares beneficially held by Dr. Zhao, and (ii) Dr. Zhao's entitlement to receive 400,000 H Shares pursuant to the Awards granted to him under the 2021 H Share Award and Trust Scheme and to receive 3,600,000 H Shares pursuant to the Awards granted to him under the 2025 Share Incentive Scheme.
- (2) This includes (i) 479,427 H Shares beneficially held by Dr. Li, and (ii) Dr. Li's entitlement to receive 200,000 H Shares pursuant to the Awards granted to him under the 2021 H Share Award and Trust Scheme and to receive 1,800,000 H Shares pursuant to the Awards granted to him under the 2025 Share Incentive Scheme.

The Board considers that the execution of the Supplemental Concert Party Agreement will not have any material effect on the financial position or operations of the Group. The Board maintains firm confidence in the long-term development prospects of the Company's business and are optimistic of the operational development and future growth potential of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, April 2, 2026

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.